摘要
目的:观察阿糖胞苷(Ara-C)、氟达拉滨(Flu)、粒细胞集落刺激因子(G—CSF)3种药物不同给药方式对髓性白血病细胞株HL-60及其耐药株HL-60/R存活率的影响。方法:分别取对数生长期的HL-60、HL-60/R细胞株,用96孔板,每孔加入浓度为1×10~9个·L^(-1)的细胞液180μL,将2种细胞株均分为3组:单药组(单加Ara-C或Flu)、联合用药组(Flu+Ara-C)、加用G-CSF组(G—CSF+Ara—C、G- CSF+Flu、G-CSF+Flu+Ara-C),于加药后不同时间段采用四氮唑蓝(MTT)还原法检测细胞存活率,同时用流式细胞仪测定加G-CSF后细胞周期的变化。结果:Flu和Ara—C两者联合应用时HL-60和HL-60/R细胞株的存活率均低于单用Ara-C或Flu(P<0.05)。G—CSF先孵育24h再与Ara—C联用时细胞的存活率低于单用Ara-C(P<0.05)。G-CSF+Flu+Ara-C(FLAG)对HL-60细胞存活率的抑制作用优于Flu、Ara—C两者联用(P<0.05);而对于HL-60/R细胞株存活率的抑制无明显差异(P>0.05)。先用G-CSF孵育24h,HL-60和HL-60/R细胞株S期细胞数均增加(P<0.05)。结论:对于HL-60和HL-60/R细胞株的存活率,Flu、G—CSF联合Ara-C有协同抑制作用,G-CSF提前24h应用为最佳时机。
AIM： To observe the interactions of different kinds of administration with granulocyte colony- stimulating factor （ G-CSF）, fludarabine （Flu） and cytarabine （Ara-C） to the leukemic cell survival （LCS） of HL-60 and HL-60/R cells in vitro. METHODS： HL-60 cells 180 μL or HL-60/R cells 180 μL in exponential phase of growth were poured separately into 96-hole plates with the cell concentration of 1 × 10^9. L^-1 and then divided into 3 groups： single drug group （Ara-C or Flu）, Ara-C＋Flu （FA） group, adding G-CSF group （G-CSF＋Ara-C. G-CSF＋Flu, G-CSF＋ Flu＋Ara-C） . After incubation for a period of time, we used MTt assay to test the LCS. The cell cycle was determined after cells exposure to G-CSF with the flow cytometer. RESULTS： The LCS of HL-60 and HL-60/R decreased significantly （P 〈 0.05） when blasts were exposed to the combination of Flu and Ara-C （FA） . The LCS of combination of prior 24 h incubation G-CSF and Ara-C was lower than using Ara-C alone （P 〈 0.05） . The inhibition of FLAG to LCS of HL-60 was higher than that of the combination of Flu and Ara-C （P 〈 0.05）, but with no significant difference to LCS of HL-60/R （P 〉 0.05） . With HL-60 cells pre-exposure to G-CSF before FA （FLAG） resulted in increase of cytotoxicity. With pre-exposure to G-CSF （24 h）, the cell population in S-phase increased. CONCLUSION： Flu, G-CSF and Ara-C have synergistic effects in inhibiting survival of HL-60 and HL-60/R cells, and 24 h prior may be the optimal duration for G-CSF adding.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2007年第8期586-590,共5页
Chinese Journal of New Drugs and Clinical Remedies
基金
上海交通大学医学院自然科学基金(04HX21014)
